Eko, a digital health company for heart and lung disease detection, announced that the U.S. FDA has cleared its Eko Murmur Analysis Software (EMAS) for detecting and characterizing murmurs found in adults and pediatric patients.

Eko’s murmur detection capabilities can identify and differentiate, between innocent and structural, heart murmurs indicative of valvular heart disease.

Valvular heart disease is a life-threatening condition diagnosed in more than 8 million Americans1 and is often first identified with a stethoscope. While early detection is critical, millions of patients are expected to be undiagnosed, with as much as 57% of clinically significant valvular heart disease missed.2

“This latest FDA clearance is another way in which Eko is improving access to better heart health through clinically-validated algorithms and best-in-class medical devices,” says Connor Landgraf, co-founder & CEO of Eko. “By making heart disease screening algorithms and digital stethoscopes accessible in exam rooms around the country, we are moving towards a future in which more objective and consistent valvular heart disease screening can become the standard of care.”

The EMAS algorithm aims to improve the performance of healthcare professionals to identify valvular heart disease accurately and consistently. It features an overall sensitivity of 85.6% and specificity of 84.4%.3 Further analysis showed that among adults 18 years and older, the EMAS algorithm identified structural murmurs with a sensitivity of 90.2% and specificity of 90.6%.When using traditional stethoscopes to detect significant valvular heart disease, general practitioners (GPs) were found to have a sensitivity of 44% and specificity of 69%.5

“Combining pathologic murmur detection with the stethoscope, a tool already deeply embedded in the practice of medicine, will allow for more accurate and efficient screening of heart valve disease in the community,” says Patrick McCarthy, MD, executive director of the Bluhm Cardiovascular Institute at Northwestern Medicine. “Eko’s platform will help uncover early valvular heart disease in millions of people worldwide who may otherwise be missed, and make a significant impact on our ability to treat patients with life-saving interventions.”


  1. Centers for Disease Control and Prevention, Heart Disease, www.cdc.gov/heartdisease/valvular_disease.htm
  2. d’Arcy JL, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study, European Heart Journal (2016) 37, 3515-3522. doi:10.1093/eurheartj/ehw229
  3. FDA 510(k) Summary, K213794
  4. Eko Murmur Analysis Software User Manual
  5. Gardezi SKM, et al. Cardiac auscultation poorly predicts the presence of valvular heart disease in asymptomatic primary care patients, Heart 2018;104:1832–1835. doi:10.1136/heartjnl-2018-313082

Photo: Eko